Cargando…

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis

BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different do...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Hou, Helei, Zhang, Chuantao, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178936/
https://www.ncbi.nlm.nih.gov/pubmed/30323627
http://dx.doi.org/10.2147/OTT.S176429
_version_ 1783362014408605696
author Sun, Dantong
Hou, Helei
Zhang, Chuantao
Zhang, Xiaochun
author_facet Sun, Dantong
Hou, Helei
Zhang, Chuantao
Zhang, Xiaochun
author_sort Sun, Dantong
collection PubMed
description BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), which has resulted in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of apatinib. METHODS: In total, 21 studies from five databases (PubMed, ScienceDirect, ClinicalTrials.gov, China National Knowledge Infrastructure [CNKI], and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-analysis were performed using Stata 14.0 software. We used objective response rate (ORR) and disease control rate (DCR) to evaluate the efficacy of apatinib for five major types of solid tumors. Additionally, we used the total incidence of AEs and the incidence of the three most common grade 3–4 AEs to evaluate the safety of apatinib. RESULTS: The pooled results for the efficacy of apatinib in the treatment of different types of solid tumors revealed that patients treated with apatinib exhibited good disease control. In addition, it was likely that an increased dose of apatinib resulted in an increased ORR in lung and breast cancer and an increased DCR in liver and gastric cancer. Although AEs appeared in 84% of patients included in this meta-analysis, most of these AEs were of grades 1–2 and were well tolerated and controlled. The most common grade 3–4 AEs included hypertension, hand-foot syndrome, and proteinuria. Importantly, there were no significant differences in these grade 3–4 AEs with higher doses of apatinib. CONCLUSION: Apatinib is a novel VEGFR-2 inhibitor with proven efficacy and safety for solid tumors. The meta-analysis reveals the broad-spectrum anticancer effect of apatinib.
format Online
Article
Text
id pubmed-6178936
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61789362018-10-15 The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis Sun, Dantong Hou, Helei Zhang, Chuantao Zhang, Xiaochun Onco Targets Ther Original Research BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), which has resulted in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of apatinib. METHODS: In total, 21 studies from five databases (PubMed, ScienceDirect, ClinicalTrials.gov, China National Knowledge Infrastructure [CNKI], and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-analysis were performed using Stata 14.0 software. We used objective response rate (ORR) and disease control rate (DCR) to evaluate the efficacy of apatinib for five major types of solid tumors. Additionally, we used the total incidence of AEs and the incidence of the three most common grade 3–4 AEs to evaluate the safety of apatinib. RESULTS: The pooled results for the efficacy of apatinib in the treatment of different types of solid tumors revealed that patients treated with apatinib exhibited good disease control. In addition, it was likely that an increased dose of apatinib resulted in an increased ORR in lung and breast cancer and an increased DCR in liver and gastric cancer. Although AEs appeared in 84% of patients included in this meta-analysis, most of these AEs were of grades 1–2 and were well tolerated and controlled. The most common grade 3–4 AEs included hypertension, hand-foot syndrome, and proteinuria. Importantly, there were no significant differences in these grade 3–4 AEs with higher doses of apatinib. CONCLUSION: Apatinib is a novel VEGFR-2 inhibitor with proven efficacy and safety for solid tumors. The meta-analysis reveals the broad-spectrum anticancer effect of apatinib. Dove Medical Press 2018-10-05 /pmc/articles/PMC6178936/ /pubmed/30323627 http://dx.doi.org/10.2147/OTT.S176429 Text en © 2018 Sun et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sun, Dantong
Hou, Helei
Zhang, Chuantao
Zhang, Xiaochun
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title_full The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title_fullStr The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title_full_unstemmed The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title_short The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
title_sort efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178936/
https://www.ncbi.nlm.nih.gov/pubmed/30323627
http://dx.doi.org/10.2147/OTT.S176429
work_keys_str_mv AT sundantong theefficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT houhelei theefficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT zhangchuantao theefficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT zhangxiaochun theefficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT sundantong efficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT houhelei efficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT zhangchuantao efficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis
AT zhangxiaochun efficacyandsafetyofapatinibforrefractorymalignanciesareviewandmetaanalysis